

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

## PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 80398

Title: Emerging novel targets for nonalcoholic fatty liver disease treatment: evidence

from recent basic studies

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 03475142 Position: Peer Reviewer

Academic degree: MD, PhD

**Professional title:** Assistant Professor

Reviewer's Country/Territory: Japan

Author's Country/Territory: China

Manuscript submission date: 2022-10-04

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-10-07 08:37

Reviewer performed review: 2022-10-16 15:50

**Review time:** 9 Days and 7 Hours

Scientific quality	[ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ Y] Grade A: Priority publishing [ ] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[Y]Yes [ ]No



## Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568 E-mail: bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer statements

Peer-Review: [Y] Anonymous [] Onymous

Conflicts-of-Interest: [ ] Yes [ Y] No

## SPECIFIC COMMENTS TO AUTHORS

The manuscript was reviewed for publication in the journal. The manuscript was designed to review emerging novel targets for NASH treatment. It is the reviewer's opinion that the review is quite interesting and easy to follow. However, it appears that there are a couple of minor concerns in the manuscript. 1) The authors discussed the potential targets outside the liver. How about other targets such as the systemic or metabolic effects? The authors should discuss the issue. 2) The authors have discussed the cell specific effects for NASH treatment. How about the specific effects of liver immune cells such as lymphocytes, neutrophils, and other cells? The authors should discuss the issue.



7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

## PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 80398

Title: Emerging novel targets for nonalcoholic fatty liver disease treatment: evidence

from recent basic studies

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 06360124 Position: Peer Reviewer Academic degree: PhD

**Professional title:** Assistant Professor

Reviewer's Country/Territory: Iran

Author's Country/Territory: China

Manuscript submission date: 2022-10-04

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-11-01 18:36

Reviewer performed review: 2022-11-10 05:58

**Review time:** 8 Days and 11 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	[ ] Grade A: Priority publishing [ Y] Grade B: Minor language polishing [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection
Conclusion	[ ] Accept (High priority) [ ] Accept (General priority) [ Y] Minor revision [ ] Major revision [ ] Rejection
Re-review	[ ]Yes [Y]No



# Baishideng **Publishing**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com

https://www.wjgnet.com

Peer-reviewer

Peer-Review: [Y] Anonymous [] Onymous

statements Conflicts-of-Interest: [ ] Yes [Y] No

## SPECIFIC COMMENTS TO AUTHORS

This review focuses on recent researches reporting the mechanism underlying the pathogenesis of NASH. This research also tries to compile signaling pathways targeting key mechanisms that contribute to NASH development. The authors try to open new insights into explored the mechanism of NASH and its novel therapeutic targets. This study focused on basic cellular and molecular mechanisms and did not discuss subsequent pathological and also therapeutic outcomes in every research. However, it seems that approaches target signaling pathways driving disease development can use to inform new treatments for precision medicine. Therefore, it may provide a novel platform to identify and prioritize novel targets for NAFLD and NASH, creating a path for drug developers towards a first-in-class treatment.